Amyotrophic Lateral Sclerosis Competitive Landscape Market Insights Epidemiology And Market Forecast

"Amyotrophic Lateral Sclerosis - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2027", report provides comprehensive insights about marketed and pipeline drugs across this indication.


The report covers an overview of the disease along with global historical and forecasted epidemiological data of Amyotrophic Lateral Sclerosis for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan till 2027. Details about the current treatment practices and guidelines provided by the regulatory bodies of US and Europe. This report further provides comprehensive insights about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis. Furthermore, the report provides the detailed analysis of 70+ products along with 65+ companies involved. 

Products covered by Phase

• Marketed Products

• Filed, Phase III, Phase II and Phase I

• Pre-clinical and Discovery

Overview of pipeline development activities for Amyotrophic Lateral Sclerosis

Pipeline analysis of 70+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.


Therapeutic segmentation of products for Amyotrophic Lateral Sclerosis

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.


Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.


Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope

  • The report provides competitive pipeline landscape of Amyotrophic Lateral Sclerosis
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Amyotrophic Lateral Sclerosis
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Establish a comprehensive understanding of the current pipeline scenario Amyotrophic Lateral Sclerosis to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Amyotrophic Lateral Sclerosis R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of indication therapeutics
  • Developing strategic initiatives to support your drug development activities
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Amyotrophic Lateral Sclerosis to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
  • Gaining a full picture of the Competitive Landscape for Evidence based Decisions



Executive Summary

Amyotrophic Lateral Sclerosis (ALS)

Disease Overview

Types

Stages

Causes

Pathophysiology

Symptoms

Risk Factors

Management of Amyotrophic Lateral Sclerosis

Diagnosis

Treatment

International Guidelines for the clinical management of Amyotrophic Lateral Sclerosis

Europe

United Kingdom

United States

Treatment Algorithm

Nutritional Treatment Algorithm

Respiratory Treatment Algorithm

Drug therapy Treatment Algorithm

Competitive Landscape

Designations

Marketed Products

Rilutek: Sanofi

Product Description

Research and Development

Product Development Activities

(The list continues)

Pipeline Therapeutics (Phase Products)

Pipeline Therapeutics (Early Phase Products)

Pipeline Therapeutics (Inactive Products)

Comparative Analysis

Late Stage Products (Filed and Phase III)

Comparative Analysis

Masitinib: AB Science

Product Description

Research and Development

Product Development Activities

(The list continues)

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I)

Comparative Analysis

Therapeutic Assessment: Phase Products

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Pre-clinical and Discovery Products

Comparative Analysis

Dormant & Discontinued Products

Comparative Analysis

Key Findings on Epidemiology of ALS

7MM

Assumptions and Rationale

Incidence of ALS in 7MM

Incident Cases of ALS in 7MM

ALS Type Specific Incident Cases in 7MM

Age Specific Incidence of ALS in 7MM

Gender Specific Incidence of ALS in 7MM

Prevalence of ALS in 7MM

Prevalent Cases of ALS in 7MM

ALS Type Specific Prevalent Cases in 7MM

Age Specific Prevalence of ALS in 7MM

Gender Specific Prevalence of ALS in 7MM

United States

Assumptions and Rationale

Incident Cases of ALS in United States

ALS Type Specific Incident Cases in United States

Age Specific Incidence of ALS in United States

Gender Specific Incidence of ALS in United States

Race Specific Incidence of ALS in United States

Prevalent Cases of ALS in United States

ALS Type Specific Prevalent Cases in United States

Age Specific Prevalence of ALS in United States

Gender Specific Prevalence of ALS in United States

Race Specific Prevalence of ALS in United States

United Kingdom

Assumptions and Rationale

Incident Cases of ALS in United Kingdom

ALS Type Specific Incident Cases in United Kingdom

Age Specific Incidence of ALS in United Kingdom

Gender Specific Incidence of ALS in United Kingdom

Race Specific Incidence of ALS in United Kingdom

Prevalent Cases of ALS in United Kingdom

ALS Type Specific Prevalent Cases in United Kingdom

Age Specific Prevalence of ALS in United Kingdom

Gender Specific Prevalence of ALS in United Kingdom

Race Specific Prevalence of ALS in United Kingdom

France

Assumptions and Rationale

Incident Cases of ALS in France

ALS Type Specific Incident Cases in France

Age Specific Incidence of ALS in France

Gender Specific Incidence of ALS in France

Race Specific Incidence of ALS in France

Prevalent Cases of ALS in France

ALS Type Specific Prevalent Cases in France

Age Specific Prevalence of ALS in France

Gender Specific Prevalence of ALS in France

Race Specific Prevalence of ALS in France

Italy

Assumptions and Rationale

Incident Cases of ALS in Italy

ALS Type Specific Incident Cases in Italy

Age Specific Incidence of ALS in Italy

Gender Specific Incidence of ALS in Italy

Race Specific Incidence of ALS in Italy

Prevalent Cases of ALS in Italy

ALS Type Specific Prevalent Cases in Italy

Age Specific Prevalence of ALS in Italy

Gender Specific Prevalence of ALS in Italy

Race Specific Prevalence of ALS in Italy

Spain

Assumptions and Rationale

Incident Cases of ALS in Spain

ALS Type Specific Incident Cases in Spain

Age Specific Incidence of ALS in Spain

Gender Specific Incidence of ALS in Spain

Race Specific Incidence of ALS in Spain

Prevalent Cases of ALS in Spain

ALS Type Specific Prevalent Cases in Spain

Age Specific Prevalence of ALS in Spain

Gender Specific Prevalence of ALS in Spain

Race Specific Prevalence of ALS in Spain

Germany

Assumptions and Rationale

Incident Cases of ALS in Germany

ALS Type Specific Incident Cases in Germany

Age Specific Incidence of ALS in Germany

Gender Specific Incidence of ALS in Germany

Race Specific Incidence of ALS in Germany

Prevalent Cases of ALS in Germany

ALS Type Specific Prevalent Cases in Germany

Age Specific Prevalence of ALS in Germany

Gender Specific Prevalence of ALS in Germany

Race Specific Prevalence of ALS in Germany

Japan

Assumptions and Rationale

Incident Cases of ALS in Japan

ALS Type Specific Incident Cases in Japan

Age Specific Incidence of ALS in Japan

Gender Specific Incidence of ALS in Japan

Prevalent Cases of ALS in Japan

ALS Type Specific Prevalent Cases in Japan

Age Specific Prevalence of ALS in Japan

Gender Specific Prevalence of ALS in Japan

Global Epidemiology of ALS

Assumptions and Rationale

Global Incidence of ALS

Global Incident Cases of ALS

Global ALS Type Specific Incident Cases

Global Age Specific Incidence of ALS

Global Gender Specific Incidence of ALS

Global Prevalence of ALS

Global Prevalent Cases of ALS

Global ALS Type Specific Prevalent Cases

Global Age Specific Prevalence of ALS

Global Gender Specific Prevalence of ALS

Europe

Assumptions and Rationale

Incidence of ALS in EU5

Incident Cases of ALS in EU5

ALS Type Specific Incident Cases in EU5

Age Specific Incidence of ALS in EU5

Gender Specific Incidence of ALS in EU5

Race Specific Incidence of ALS in EU5

Prevalence of ALS in EU5

Prevalent Cases of ALS in EU5

ALS Type Specific Prevalent Cases in EU5

Age Specific Prevalence of ALS in EU5

Gender Specific Prevalence of ALS in EU5

RoW

Assumptions and Rationale

Incident Cases of ALS in RoW

ALS Type Specific Incident Cases in Spain

Age Specific Incidence of ALS in RoW

Gender Specific Incidence of ALS in RoW

Race Specific Incidence of ALS in RoW

Prevalent Cases of ALS in RoW

ALS Type Specific Prevalent Cases in Spain

Age Specific Prevalence of ALS in RoW

Gender Specific Prevalence of ALS in RoW

Market Outlook

United States Market Assessment

United States Market Size

United States: Market Share

Europe Market Assessment

Europe Market Size

Europe: Market Share

Japan Market Assessment

Japan Market Size

Japan: Market Share

RoW Market Assessment

RoW Market Size

RoW: Market Share

Global Market Assessment

Global Market Size

Global: Market Shares

Market Drivers and Barriers

Appendix

Table 1: Drug Designations

Table 2: Total Products for Amyotrophic Lateral Sclerosis

Table 3: Late Stage Products (Filed and Phase III)

Table 4: Mid Stage Products (Phase II)

Table 5: Early Stage Products (Phase I)

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Combination Products

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Pre-clinical and Discovery Stage Products

Table 13: Dormant Products

Table 14: Discontinued Products

Table 15: 7MM, ALS Incident Cases, 2015-2027

Table 16: 7MM, ALS Type Specific Incident Cases, 2015-2027

Table 17: 7MM, Age Specific Incidence of ALS, 2015-2027

Table 18:7MM, Gender Specific Incidence of ALS, 2015-2027

Table 19: 7MM, ALS Prevalent Cases, 2015-2027

Table 20: 7MM, ALS Type Specific Prevalent Cases, 2015-2027

Table 21: 7MM, Age Specific Prevalence of ALS, 2015-2027

Table 22: 7MM, Gender Specific Prevalence of ALS, 2015-2027

Table 23: United States, ALS Incident Cases, 2015-2027

Table 24: United States, ALS Type Specific Incident Cases, 2015-2027

Table 25:United States, Age Specific Incidence of ALS, 2015-2027

Table 26: United States, Gender Specific Incidence of ALS, 2015-2027

Table 27: United States, Race Specific Incidence of ALS, 2015-2027

Table 28: United States, ALS Prevalent Cases, 2015-2027

Table 29: United States, ALS Type Specific Prevalent Cases, 2015-2027

Table 30: United States, Age Specific Prevalence of ALS, 2015-2027

Table 31: United States, Gender Specific Prevalence of ALS, 2015-2027

Table 32: United States, Race Specific Prevalence of ALS, 2015-2027

Table 33: United Kingdom, ALS Incident Cases, 2015-2027

Table 34: United Kingdom, ALS Type Specific Incident Cases, 2015-2027

Table 35: United Kingdom, Age Specific Incidence of ALS, 2015-2027

Table 36: United Kingdom, Gender Specific Incidence of ALS, 2015-2027

Table 37: United Kingdom, Race Specific Incidence of ALS, 2015-2027

Table 38: United Kingdom, ALS Prevalent Cases, 2015-2027

Table 39: United Kingdom, ALS Type Specific Prevalent Cases, 2015-2027

Table 40: United Kingdom, Age Specific Prevalence of ALS, 2015-2027

Table 41: United Kingdom, Gender Specific Prevalence of ALS, 2015-2027

Table 42: United Kingdom, Race Specific Prevalence of ALS, 2015-2027

Table 43: France, ALS Incident Cases, 2015-2027

Table 44: France, ALS Type Specific Incident Cases, 2015-2027

Table 45: France, Age Specific Incidence of ALS, 2015-2027

Table 46: France, Gender Specific Incidence of ALS, 2015-2027

Table 47: France, Race Specific Incidence of ALS, 2015-2027

Table 48: France, ALS Prevalent Cases, 2015-2027

Table 49: France, ALS Type Specific Prevalent Cases, 2015-2027

Table 50: France, Age Specific Prevalence of ALS, 2015-2027

Table 51: France, Gender Specific Prevalence of ALS, 2015-2027

Table 52: France, Race Specific Prevalence of ALS, 2015-2027

Table 53: Italy, ALS Incident Cases, 2015-2027

Table 54: Italy, ALS Type Specific Incident Cases, 2015-2027

Table 55: Italy, Age Specific Incidence of ALS, 2015-2027

Table 56: Italy, Gender Specific Incidence of ALS, 2015-2027

Table 57: Italy, Race Specific Incidence of ALS, 2015-2027

Table 58: Italy, ALS Prevalent Cases, 2015-2027

Table 59: Italy, ALS Type Specific Prevalent Cases, 2015-2027

Table 60: Italy, Age Specific Prevalence of ALS, 2015-2027

Table 61: Italy, Gender Specific Prevalence of ALS, 2015-2027

Table 62: Italy, Race Specific Prevalence of ALS, 2015-2027

Table 63: Spain, ALS Incident Cases, 2015-2027

Table 64: Spain, ALS Type Specific Incident Cases, 2015-2027

Table 65: Spain, Age Specific Incidence of ALS, 2015-2027

Table 66: Spain, Gender Specific Incidence of ALS, 2015-2027

Table 67: Spain, Race Specific Incidence of ALS, 2015-2027

Table 68: Spain, ALS Prevalent Cases, 2015-2027

Table 69: Spain, ALS Type Specific Prevalent Cases, 2015-2027

Table 70: Spain, Age Specific Prevalence of ALS, 2015-2027

Table 71: Spain, Gender Specific Prevalence of ALS, 2015-2027

Table 72: Spain, Race Specific Prevalence of ALS, 2015-2027

Table 73: Germany, ALS Incident Cases, 2015-2027

Table 74: Germany, ALS Type Specific Incident Cases, 2015-2027

Table 75: Germany, Age Specific Incidence of ALS, 2015-2027

Table 76: Germany, Gender Specific Incidence of ALS, 2015-2027

Table 77: Germany, Race Specific Incidence of ALS, 2015-2027

Table 78: Germany, ALS Prevalent Cases, 2015-2027

Table 79: Germany, ALS Type Specific Prevalent Cases, 2015-2027

Table 80: Germany, Age Specific Prevalence of ALS, 2015-2027

Table 81: Germany, Gender Specific Prevalence of ALS, 2015-2027

Table 82: Germany, Race Specific Prevalence of ALS, 2015-2027

Table 83: Japan, ALS Incident Cases, 2015-2027

Table 84: Japan, ALS Type Specific Incident Cases, 2015-2027

Table 85: Japan, Age Specific Incidence of ALS, 2015-2027

Table 86: Japan, Gender Specific Incidence of ALS, 2015-2027

Table 87: Japan, ALS Prevalent Cases, 2015-2027

Table 88: Japan, ALS Type Specific Prevalent Cases, 2015-2027

Table 89: Japan, Age Specific Prevalence of ALS, 2015-2027

Table 90: Japan, Gender Specific Prevalence of ALS, 2015-2027

Table 91: Global, ALS Incident Cases, 2015-2027

Table 92: Global, ALS Type Specific Incident Cases, 2015-2027

Table 93: Global, Age Specific Incidence of ALS, 2015-2027

Table 94: Global, Gender Specific Incidence of ALS, 2015-2027

Table 95: Global, ALS Prevalent Cases, 2015-2027

Table 96: Global, ALS Type Specific Prevalent Cases, 2015-2027

Table 97: Global, Age Specific Prevalence of ALS, 2015-2027

Table 98: Global, Gender Specific Prevalence of ALS, 2015-2027

Table 99: EU5, ALS Incident Cases, 2015-2027

Table 100: EU5, ALS Type Specific Incident Cases, 2015-2027

Table 101: EU5, Age Specific Incidence of ALS, 2015-2027

Table 102: EU5, Gender Specific Incidence of ALS, 2015-2027

Table 103: EU5, Race Specific Incidence of ALS, 2015-2027

Table 104: EU5, ALS Prevalent Cases, 2015-2027

Table 105: EU5, ALS Type Specific Prevalent Cases, 2015-2027

Table 106: EU5, Age Specific Prevalence of ALS, 2015-2027

Table 107: EU5, Gender Specific Prevalence of ALS, 2015-2027

Table 108: RoW, ALS Incident Cases, 2015-2027

Table 109: RoW, ALS Type Specific Incident Cases, 2015-2027

Table 110: RoW, Age Specific Incidence of ALS, 2015-2027

Table 111: RoW, Gender Specific Incidence of ALS, 2015-2027

Table 112: RoW, Race Specific Incidence of ALS, 2015-2027

Table 113: RoW, ALS Prevalent Cases, 2015-2027

Table 114: RoW, ALS Type Specific Prevalent Cases, 2015-2027

Table 115: RoW, Age Specific Prevalence of ALS, 2015-2027

Table 116:RoW, Gender Specific Prevalence of ALS, 2015-2027

Figure 1: Schematic representation of Amyotrophic Lateral Sclerosis

Figure 2: Pathophysiology of Amyotrophic Lateral Sclerosis

Figure 3: Drug Designations

Figure 4: Total Products for Amyotrophic Lateral Sclerosis

Figure 5: Late Stage Products (Filed and Phase III)

Figure 6: Mid Stage Products (Phase II)

Figure 7: Early Stage Products (Phase I)

Figure 8: Assessment by Monotherapy Products

Figure 9: Assessment by Route of Administration

Figure 10: Assessment by Stage and Route of Administration

Figure 11: Assessment by Molecule Type

Figure 12: Assessment by Stage and Molecule Type

Figure 13: Pre-clinical Stage and Discovery Products

Figure 14: Dormant & Discontinued Products

Figure 15: 7MM, ALS Incident Cases, 2015-2027

Figure 16: 7MM, ALS Type Specific Incident Cases, 2015-2027

Figure 17: 7MM, Age Specific Incidence of ALS, 2015-2027

Figure 18: 7MM, Gender Specific Incidence of ALS, 2015-2027

Figure 19:7MM, ALS Prevalent Cases, 2015-2027

Figure 20: 7MM, ALS Type Specific Prevalent Cases, 2015-2027

Figure 21: 7MM, Age Specific Prevalence of ALS, 2015-2027

Figure 22: 7MM, Gender Specific Prevalence of ALS, 2015-2027

Figure 23: United States, ALS Incident Cases, 2015-2027

Figure 24: United States, ALS Type Specific Incident Cases, 2015-2027

Figure 25:United States, Age Specific Incidence of ALS, 2015-2027

Figure 26: United States, Gender Specific Incidence of ALS, 2015-2027

Figure 27: United States, Race Specific Incidence of ALS, 2015-2027

Figure 28: United States, ALS Prevalent Cases, 2015-2027

Figure 29: United States, ALS Type Specific Prevalent Cases, 2015-2027

Figure 30: United States, Age Specific Prevalence of ALS, 2015-2027

Figure 31: United States, Gender Specific Prevalence of ALS, 2015-2027

Figure 32: United States, Race Specific Prevalence of ALS, 2015-2027

Figure 33: United Kingdom, ALS Incident Cases, 2015-2027

Figure 34: United Kingdom, ALS Type Specific Incident Cases, 2015-2027

Figure 35: United Kingdom, Age Specific Incidence of ALS, 2015-2027

Figure 36: United Kingdom, Gender Specific Incidence of ALS, 2015-2027

Figure 37: United Kingdom, Race Specific Incidence of ALS, 2015-2027

Figure 38: United Kingdom, ALS Prevalent Cases, 2015-2027

Figure 39: United Kingdom, ALS Type Specific Prevalent Cases, 2015-2027

Figure 40: United Kingdom, Age Specific Prevalence of ALS, 2015-2027

Figure 41: United Kingdom, Gender Specific Prevalence of ALS, 2015-2027

Figure 42: United Kingdom, Race Specific Prevalence of ALS, 2015-2027

Figure 43: France, ALS Incident Cases, 2015-2027

Figure 44: France, ALS Type Specific Incident Cases, 2015-2027

Figure 45: France, Age Specific Incidence of ALS, 2015-2027

Figure 46: France, Gender Specific Incidence of ALS, 2015-2027

Figure 47: France, Race Specific Incidence of ALS, 2015-2027

Figure 48: France, ALS Prevalent Cases, 2015-2027

Figure 49: France, ALS Type Specific Prevalent Cases, 2015-2027

Figure 50: France, Age Specific Prevalence of ALS, 2015-2027

Figure 51: France, Gender Specific Prevalence of ALS, 2015-2027

Figure 52: France, Race Specific Prevalence of ALS, 2015-2027

Figure 53: Italy, ALS Incident Cases, 2015-2027

Figure 54: Italy, ALS Type Specific Incident Cases, 2015-2027

Figure 55: Italy, Age Specific Incidence of ALS, 2015-2027

Figure 56: Italy, Gender Specific Incidence of ALS, 2015-2027

Figure 57: Italy, Race Specific Incidence of ALS, 2015-2027

Figure 58: Italy, ALS Prevalent Cases, 2015-2027

Figure 59: Italy, ALS Type Specific Prevalent Cases, 2015-2027

Figure 60: Italy, Age Specific Prevalence of ALS, 2015-2027

Figure 61: Italy, Gender Specific Prevalence of ALS, 2015-2027

Figure 62: Italy, Race Specific Prevalence of ALS, 2015-2027

Figure 63: Spain, ALS Incident Cases, 2015-2027

Figure 64: Spain, ALS Type Specific Incident Cases, 2015-2027

Figure 65: Spain, Age Specific Incidence of ALS, 2015-2027

Figure 66: Spain, Gender Specific Incidence of ALS, 2015-2027

Figure 67: Spain, Race Specific Incidence of ALS, 2015-2027

Figure 68: Spain, ALS Prevalent Cases, 2015-2027

Figure 69: Spain, ALS Type Specific Prevalent Cases, 2015-2027

Figure 70: Spain, Age Specific Prevalence of ALS, 2015-2027

Figure 71: Spain, Gender Specific Prevalence of ALS, 2015-2027

Figure 72: Spain, Race Specific Prevalence of ALS, 2015-2027

Figure 73: Germany, ALS Incident Cases, 2015-2027

Figure 74: Germany, ALS Type Specific Incident Cases, 2015-2027

Figure 75: Germany, Age Specific Incidence of ALS, 2015-2027

Figure 76: Germany, Gender Specific Incidence of ALS, 2015-2027

Figure 77: Germany, Race Specific Incidence of ALS, 2015-2027

Figure 78: Germany, ALS Prevalent Cases, 2015-2027

Figure 79: Germany, ALS Type Specific Prevalent Cases, 2015-2027

Figure 80: Germany, Age Specific Prevalence of ALS, 2015-2027

Figure 81: Germany, Gender Specific Prevalence of ALS, 2015-2027

Figure 82: Germany, Race Specific Prevalence of ALS, 2015-2027

Figure 83: Japan, ALS Incident Cases, 2015-2027

Figure 84: Japan, ALS Type Specific Incident Cases, 2015-2027

Figure 85: Japan, Age Specific Incidence of ALS, 2015-2027

Figure 86: Japan, Gender Specific Incidence of ALS, 2015-2027

Figure 87: Japan, ALS Prevalent Cases, 2015-2027

Figure 88: Japan, ALS Type Specific Prevalent Cases, 2015-2027

Figure 89: Japan, Age Specific Prevalence of ALS, 2015-2027

Figure 90: Japan, Gender Specific Prevalence of ALS, 2015-2027

Figure 91: Global, ALS Incident Cases, 2015-2027

Figure 92: Global, ALS Type Specific Incident Cases, 2015-2027

Figure 93: Global, Age Specific Incidence of ALS, 2015-2027

Figure 94: Global, Gender Specific Incidence of ALS, 2015-2027

Figure 95: Global, ALS Prevalent Cases, 2015-2027

Figure 96: Global, ALS Type Specific Prevalent Cases, 2015-2027

Figure 97: Global, Age Specific Prevalence of ALS, 2015-2027

Figure 98: Global, Gender Specific Prevalence of ALS, 2015-2027

Figure 99: EU5, ALS Incident Cases, 2015-2027

Figure 100: EU5, ALS Type Specific Incident Cases, 2015-2027

Figure 101: EU5, Age Specific Incidence of ALS, 2015-2027

Figure 102: EU5, Gender Specific Incidence of ALS, 2015-2027

Figure 103: EU5, Race Specific Incidence of ALS, 2015-2027

Figure 104: EU5, ALS Prevalent Cases, 2015-2027

Figure 105: EU5, ALS Type Specific Prevalent Cases, 2015-2027

Figure 106: EU5, Age Specific Prevalence of ALS, 2015-2027

Figure 107: EU5, Gender Specific Prevalence of ALS, 2015-2027

Figure 108: RoW, ALS Incident Cases, 2015-2027

Figure 109: RoW, ALS Type Specific Incident Cases, 2015-2027

Figure 110: RoW, Age Specific Incidence of ALS, 2015-2027

Figure 111: RoW, Gender Specific Incidence of ALS, 2015-2027

Figure 112: RoW, Race Specific Incidence of ALS, 2015-2027

Figure 113: RoW, ALS Prevalent Cases, 2015-2027

Figure 114: RoW, ALS Type Specific Prevalent Cases, 2015-2027

Figure 115: RoW, Age Specific Prevalence of ALS, 2015-2027

Figure 116: RoW, Gender Specific Prevalence of ALS, 2015-2027

Figure 117: United States Market Size

Figure 118: Europe Market Size

Figure 119: Japan Market Size

Figure 120: RoW Market Size

Figure 121: Global Market Size

2-BBB Medicines

AB Science

Amylyx Pharmaceuticals

Anavex Life Sciences

Anida Pharma

ApoPharma

ArmaGen

BioCrea

Biogen

Biohaven Pharmaceuticals

BioHealthonomics

BrainStorm Cell Therapeutics

Calico

Catabasis Pharmaceuticals

Ceregen

Chemigen

Chronos Therapeutics

Corcept Therapeutics

Coyote Pharmaceuticals

Cytokinetics

Daval International

Edison Pharmaceuticals

Eisai Co

Ensemble Therapeutics

Evotec

Flex Pharma

Genentech

Genervon Biopharmaceuticals

GeNeuro

Glialogix

Grifols

Herantis Pharma

ImStar Therapeutics

Ionis Pharmaceuticals

Jeil Pharmaceutical

Kadimastem

Karyopharm Therapeutics

KineMed

Kringle Pharma

LifeSplice

Mallinckrodt

Medicinova

miRagen Therapeutics

M's Science

Neuralgene

Neuralstem

Neuraltus Pharmaceuticals

Neurimmune Holding

Orion Pharma

Orphazyme

Pharnext

Plex Pharmaceuticals

ProMIS Neurosciences

Reata Pharmaceuticals

Regenesance

reMYND

Revalsio

SciFluor Life Sciences

SK Biopharmaceuticals

Tarix Orphan

TheraNeuro

Treeway

ViroMed

Voyager Therapeutics

Xencor

YooYoung Pharmaceuticals

  • Tags:
  • Amyotrophic Lateral Sclerosis - Com...
  • Market Insights
  • Epidemiology and Market Forecast-2...

Forward to Friend

Need A Quote